J Korean Med Assoc Search

CLOSE


J Korean Med Assoc > Volume 50(4); 2007 > Article
Choi: HIV/AIDS Vaccine

Abstract

Recent researches have suggested approaches to HIV immunization that might result in at least a partially effective vaccine against infection with HIV-1. In particular, advances in our understanding of animal models, the vaccine-elicited celluar immunity and neutralizing antibody provide rational strategies for the development of this vaccine. Some advanced-phase clinical trials of HIV vaccine are ongoing. Although the creation of an effective HIV-1 vaccine remains an enormous challenge, the continuing progress in these areas provides a reason to be optimistic about our ultimate ability to control the spread of AIDS.

References

1. Borkow G. Mouse models for HIV-1 infection. IUBMB Life 2005;57:819-823.

2. Sharp PM, Shaw GM, Hahn BH. Simian immunodeficiency virus infection of chimpanzees. J Virol 2005;79:3891-3902.

3. Letvin NL, King NW. Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Acquir Immune Defic Sydr 1990;3:1023-1040.

4. Reimann KA, Li JT, Vaazey R, Halloran M, Park IW, Karlsson GB, Sodroski J, Letvin NL. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996;70:6922-6928.

5. Le Rouzic E, Benichou S. The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 2005;2:11.

6. Joag SV. Primate models of AIDS. Microbes Infect 2000;2:223-229.

7. Plotkin SA. Immunologic correlates of protection induced by vaccinatin. Pediatr Infect Dis J 2001;20:63-75.

8. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;73:4009-4018.

9. Conley AJ, Kessler JA II, Boots LJ, McKenna PM, Schleif WA, Emini EA, Mark GE III, Katinger H, Cobb EK, Lunceford SM, Rouse SR, Murthy KK. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 1996;70:6751-6758.

10. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg JW, Murthy KK. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992;355:728-730.

11. Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE. NIAID HIV Vaccine Trial Network. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine 2003;21:2933-2947.

12. de Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, Burke D, Evans TG, Corey L, Keefer MC. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004;22:704-713.

13. Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Sperarman PW, Mulligan M, Goepfert P. AIDS Vaccine Evaluation Group. Safety and immunogenicity of a high-titered canarypox vac-cine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group protocol 022A. J Acquir Immune Defic Syndr 2002;29:254-261.

14. Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006;43:500-511.

15. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.

16. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz T, McMichael A, Whittle H. HIV-specific cytotoxic T-cell in HIV-exposed but uninfected Gambian woman. Nat Med 1995;1:59-64.

17. Rowland-Jones S, Dong T, Fowke KR, Kimani J, Krausa P, Newell H, Blanchard T, Ariyoshi K, Oyugi J, Ngugi E, Bwayo J, MacDonald KS, McMichael AJ, Plummer FA. Cytotoxic T cell response to multiple conserved HIV epitopes in HIV-1 resistant prostitutes in Nairobi. J Clin Invest 1998;102:1758-1765.

18. Kannagi M, Chalifoux LV, Lord CI, Letvin NL. Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. J Immunol 1988;140:2237-2242.

19. Goulder PJ, Phillips RE, Cobert RA, McAdam S, Oqq G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-217.

20. In: Plotkin SA, Orenstein WA, editor. Vaccine 2004;4th ed. Pennsylvania: Elsevier. 1219-1258.

21. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Coopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194:1661-1671.

22. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. The rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-665.

23. Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu YL, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Keefer MC, Baden LR, Corey L. NIAID HIV Vaccine Trial Network. High-dose recombinant Canarypox vaccine expressing HIV-1 protein in seronegative human subjects. J Infect Dis 2005;7:1249-1259.

24. Letvin N. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006;6:930-939.

Table 1
HIV vaccines that are currently in large clinical trials for immunogenicity and efficacy
jkma-50-337-i001-l.jpg

Further information on ongoing trials of preventive AIDS vaccines can be found in the 2006 International AIDS Vaccine Initiative report

TOOLS
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 0 Crossref
  •   Scopus
  • 1,255 View
  • 7 Download
Related articles in
J Korean Med Assoc

DNA Vaccines1997 January;40(1)

Cancer Vaccine1998 August;41(8)



ABOUT
ARTICLE CATEGORY

Browse all articles >

ARCHIVES
FOR CONTRIBUTORS
Editorial Office
37 Ichon-ro 46-gil, Yongsan-gu, Seoul
Tel: +82-2-6350-6562    Fax: +82-2-792-5208    E-mail: jkmamaster@gmail.com                

Copyright © 2024 by Korean Medical Association.

Developed in M2PI

Close layer
prev next